These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 11259329)

  • 1. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
    Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver.
    Yamano K; Yamamoto K; Kotaki H; Sawada Y; Iga T
    Drug Metab Dispos; 1999 Mar; 27(3):395-402. PubMed ID: 10064572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: implication of concentrative uptake of inhibitors into liver.
    Yamano K; Yamamoto K; Kotaki H; Takedomi S; Matsuo H; Sawada Y; Iga T
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1118-26. PubMed ID: 10688631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.
    Ito K; Ogihara K; Kanamitsu S; Itoh T
    Drug Metab Dispos; 2003 Jul; 31(7):945-54. PubMed ID: 12814973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative prediction of the interaction of midazolam and histamine H2 receptor antagonists in rats.
    Takedomi S; Matsuo H; Yamano K; Yamamoto K; Iga T; Sawada Y
    Drug Metab Dispos; 1998 Apr; 26(4):318-23. PubMed ID: 9531518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
    Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
    Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
    Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
    Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
    Perloff MD; von Moltke LL; Court MH; Kotegawa T; Shader RI; Greenblatt DJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
    Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
    Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
    Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
    Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat.
    Witherow LE; Houston JB
    J Pharmacol Exp Ther; 1999 Jul; 290(1):58-65. PubMed ID: 10381760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes.
    Warrington JS; Poku JW; von Moltke LL; Shader RI; Harmatz JS; Greenblatt DJ
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1024-31. PubMed ID: 10688619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
    Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
    Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
    Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
    Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats.
    Zhang X; Galinsky RE; Kimura RE; Quinney SK; Jones DR; Hall SD
    Drug Metab Dispos; 2010 Jan; 38(1):61-72. PubMed ID: 19797607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test.
    Cheng CL; Smith DE; Carver PL; Cox SR; Watkins PB; Blake DS; Kauffman CA; Meyer KM; Amidon GL; Stetson PL
    Clin Pharmacol Ther; 1997 May; 61(5):531-43. PubMed ID: 9164415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current cytochrome P450 phenotyping methods applied to metabolic drug-drug interaction prediction in dogs.
    Mills BM; Zaya MJ; Walters RR; Feenstra KL; White JA; Gagne J; Locuson CW
    Drug Metab Dispos; 2010 Mar; 38(3):396-404. PubMed ID: 20007294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats.
    Lai L; Hao H; Wang Q; Zheng C; Zhou F; Liu Y; Wang Y; Yu G; Kang A; Peng Y; Wang G; Chen X
    Drug Metab Dispos; 2009 Dec; 37(12):2399-407. PubMed ID: 19741040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single plasma sampling to predict oral clearance of CYP3A probe midazolam.
    Zhu B; Ou-Yang DS; Cheng ZN; Huang SL; Zhou HH
    Acta Pharmacol Sin; 2001 Jul; 22(7):634-8. PubMed ID: 11749829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.